Lisinopril Medicare Part D Coverage: Cost, Formulary Tier, and Savings in 2026

Why Medicare Part D Almost Always Covers Lisinopril

Lisinopril ranks among the most prescribed medications in the United States, with over 88 million prescriptions filled in 2022 according to ClinCalc drug usage statistics derived from MEPS survey data. Every major Part D plan design includes at least one ACE inhibitor, and lisinopril's status as a widely available generic places it on Tier 1 (preferred generic) in the vast majority of formularies. That tier carries the lowest cost-sharing.

The Centers for Medicare & Medicaid Services (CMS) requires Part D sponsors to cover at least two drugs in every pharmacologic class and "all or substantially all" drugs in six protected classes [1]. Antihypertensives are not a protected class, but the 2017 ACC/AHA Guideline for High Blood Pressure designates ACE inhibitors as first-line therapy for stage 1 hypertension, making formulary exclusion commercially impractical [2]. Plans that dropped a widely used Tier 1 generic would lose enrollees during the Annual Election Period.

Because lisinopril's average wholesale acquisition cost sits below $0.10 per tablet, plan sponsors have strong financial incentive to keep it on the lowest tier [3]. No brand-name version retains meaningful U.S. market share. Prinivil (Merck) and Zestril (AstraZeneca) are still listed with the FDA's Orange Book but account for a negligible fraction of fills [4].

What You Will Actually Pay Under Part D in 2026

The real-world copay depends on your plan, pharmacy network, and the coverage phase you are in. Most beneficiaries on a standard Part D plan will pay $0 to $15 per month for lisinopril during the initial coverage phase.

Under the Inflation Reduction Act (IRA) Part D redesign, the annual true out-of-pocket maximum dropped to $2,000 beginning January 1, 2025 [5]. Once a beneficiary's accumulated true out-of-pocket (TrOOP) spending reaches that cap, the plan and the federal reinsurance program cover 100% of remaining drug costs for the year. For a medication as inexpensive as lisinopril, reaching the cap on this drug alone is effectively impossible. The cap matters more when lisinopril is one of several prescriptions a beneficiary fills each month.

Coverage phases at a glance

The Part D benefit structure in 2026 follows four phases. During the deductible phase (up to $590 for standard plans in 2025; the 2026 figure will be published by CMS in the fall), you pay the full negotiated price. For lisinopril, that is typically $4 to $8. In the initial coverage phase, you pay your Tier 1 copay. In the former "donut hole," now restructured by the IRA, manufacturer discounts and plan contributions keep your share at 25% of the negotiated price, which for lisinopril amounts to roughly $1 to $2 [6]. After $2,000 TrOOP, you pay $0.

The Medicare Plan Finder tool lets you enter lisinopril with your dose, zip code, and preferred pharmacy to see exact copays for every available plan in your area [7].

How Lisinopril Fits Into Hypertension Treatment Under Medicare

Hypertension affects approximately 74.5% of U.S. adults aged 60 and older, according to NHANES 2017-2020 cycle data published by the CDC National Center for Health Statistics [8]. ACE inhibitors remain a cornerstone of guideline-directed therapy.

The ALLHAT trial (N=33,357), the largest antihypertensive outcomes study ever conducted, used lisinopril as its ACE inhibitor arm and found comparable all-cause mortality to chlorthalidone over 4.9 years of follow-up [9]. The 2017 ACC/AHA guideline and the 2020 International Society of Hypertension Global Practice Guidelines both recommend ACE inhibitors as one of four first-line drug classes alongside ARBs, calcium channel blockers, and thiazide diuretics [2][10].

For Medicare beneficiaries with comorbid conditions, lisinopril carries specific advantages. It reduces proteinuria and slows progression of diabetic kidney disease, as demonstrated in studies dating to the Collaborative Study Group trial of captopril (the mechanism is class-wide) [11]. The ATLAS trial (N=3,164) compared high-dose lisinopril (32.5-35 mg) versus low-dose (2.5-5 mg) in heart failure, finding a 12% lower risk of death or hospitalization with high-dose therapy (P=0.002) [12].

A cost-comparison figure showing lisinopril Part D copays across the five largest standalone PDPs would go here, sourced from the HealthRX formulary analysis database.

Part D Plans With the Lowest Lisinopril Copays

Not all Tier 1 copays are equal. Standalone Prescription Drug Plans (PDPs) and Medicare Advantage Prescription Drug plans (MA-PDs) set their own cost-sharing within CMS parameters.

Several national PDP sponsors, including SilverScript (CVS Health), Wellcare, and AARP/UnitedHealthcare, have offered $0 copays for preferred generics at preferred pharmacies in recent plan years [7]. The specific $0-copay status of lisinopril can shift year to year as sponsors renegotiate pharmacy network contracts, so always verify on the Medicare Plan Finder during Open Enrollment (October 15 through December 7).

MA-PD plans frequently bundle prescription drug coverage with medical benefits, and some offer $0 generic copays as an enrollment incentive, particularly in high-competition counties. The CMS Medicare & You handbook walks beneficiaries through plan comparison steps each year [13].

Preferred pharmacy networks matter. A plan might charge $0 at Walmart or Costco but $10 at an independent pharmacy. Mail-order options through the plan's contracted pharmacy benefit manager often carry a 90-day supply at two copays instead of three.

Extra Help (Low-Income Subsidy) and Lisinopril

The Medicare Extra Help program (also called the Low-Income Subsidy, or LIS) pays part or all of Part D premiums, deductibles, and copays for beneficiaries with limited income and resources [14]. In 2025, full Extra Help eligibility extends to those with income below 150% of the federal poverty level ($22,590 for an individual) under the IRA expansion, up from the previous 135% threshold [5].

Beneficiaries who qualify for full Extra Help pay $0 for generic drugs (or $4.50 in 2025 for non-preferred generics if income is between 135% and 150% FPL). Since lisinopril is a preferred generic on almost every formulary, the copay under full LIS is $0.

Partial Extra Help recipients pay reduced copays on a sliding scale. Even without full eligibility, the savings on a drug portfolio that includes lisinopril, a statin, metformin, and aspirin can total several hundred dollars per year.

Cash-Pay and Discount Alternatives If You Fall Into a Coverage Gap

Even outside Medicare Part D, lisinopril is one of the cheapest prescription drugs on the market. Cash-pay prices at large retail pharmacies average $4 to $10 for a 30-day supply of lisinopril 10 mg or 20 mg [15]. Several retailers offer lisinopril on their discount generic lists.

Pharmacy discount programs from GoodRx, RxSaver, and Amazon Pharmacy frequently bring the price below $4 for a 30-count supply. However, Medicare beneficiaries should be aware that CMS rules prohibit using manufacturer coupons that would count toward TrOOP on Part D drugs [16]. Discount card prices paid outside of Part D do not count toward TrOOP either, which could delay reaching the $2,000 cap for beneficiaries with higher-cost medications on the same regimen.

The practical question is straightforward. If lisinopril is your only medication, paying cash ($4-$8/month) versus a Part D copay ($0-$15/month) may make little difference. But if you take multiple drugs, filling lisinopril through Part D ensures every dollar counts toward TrOOP and the $2,000 cap.

Prior Authorization, Step Therapy, and Quantity Limits

Lisinopril almost never triggers prior authorization (PA) or step-therapy requirements under Part D. It is itself the first-line agent in the ACE inhibitor class, so there is no cheaper step to try first [2].

Quantity limits generally allow 30 tablets per 30 days (or 90 per 90 days for mail order), which aligns with once-daily dosing across all approved strengths. The FDA prescribing information for lisinopril supports once-daily dosing for hypertension, heart failure, and acute MI [17].

If your plan imposes an unexpected restriction (rare for this drug), your prescriber can submit a coverage determination request. The Part D sponsor must respond within 72 hours for a standard request or 24 hours for an expedited request under 42 CFR § 423.568 [18].

Lisinopril Safety Considerations for Medicare-Age Patients

ACE inhibitors carry class-specific risks that are especially relevant for older adults. Hyperkalemia is the most clinically significant concern, particularly in patients with chronic kidney disease (eGFR <45 mL/min/1.73m²) or those taking potassium-sparing diuretics. The RALES trial (N=1,663), though focused on spironolactone, highlighted how adding a potassium-elevating agent to an ACE inhibitor increased hyperkalemia-related hospitalizations [19].

Angioedema, though rare (incidence approximately 0.1-0.7%), is a potentially life-threatening adverse effect of all ACE inhibitors. A meta-analysis published in the Annals of Internal Medicine found that Black patients have a two- to four-fold higher risk of ACE inhibitor-associated angioedema compared to White patients [20]. This observation has led some guidelines, including the 2014 JNC 8 panel member report, to recommend calcium channel blockers or thiazides as preferred initial therapy in Black patients without proteinuria [21].

First-dose hypotension is another concern for volume-depleted elderly patients. Starting at 2.5 mg or 5 mg and titrating every one to two weeks mitigates this risk [17].

"ACE inhibitors remain among the best-studied antihypertensives we have. Over two decades of outcome data support their efficacy and safety profile in older adults, including those with heart failure and diabetic nephropathy." This reflects the position stated in the 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure, which gives ACE inhibitors a Class I recommendation for heart failure with reduced ejection fraction (HFrEF) [22].

Switching Between ACE Inhibitors and ARBs Under Part D

Some beneficiaries wonder whether an ARB like losartan offers an advantage over lisinopril. The ONTARGET trial (N=25,620) compared telmisartan to ramipril (another ACE inhibitor) and found equivalent outcomes for cardiovascular death, MI, stroke, and heart failure hospitalization [23]. The key practical difference: ARBs do not cause the dry cough that affects roughly 5-10% of ACE inhibitor users.

From a Part D cost standpoint, losartan and other generic ARBs also sit on Tier 1 with similar copays to lisinopril. Switching requires a new prescription but no prior authorization on most plans. If ACE inhibitor cough develops, an ARB swap is the standard clinical move, and Part D will cover it without friction.

The VA/DoD Clinical Practice Guideline for the Management of Hypertension explicitly notes that ACE inhibitors and ARBs are interchangeable for blood pressure outcomes, though they should never be combined due to increased renal and hyperkalemia risk shown in the ONTARGET combination arm [23][24].

Enrolling in Part D or Changing Plans

If you are newly eligible for Medicare, the Initial Enrollment Period (IEP) runs from three months before your 65th birthday month through three months after. Missing the IEP triggers a late enrollment penalty of 1% of the national base beneficiary premium per month of delay, compounding indefinitely [13].

The Annual Election Period (AEP), October 15 to December 7 each year, is the window to switch Part D plans. Beneficiaries already enrolled in Part D also have a Medicare Advantage Open Enrollment Period from January 1 to March 31, during which they can switch MA-PD plans or drop MA coverage and return to Original Medicare plus a standalone PDP [13].

For lisinopril specifically, plan shopping is less about the drug itself (it is cheap on every plan) and more about optimizing total portfolio cost. Enter all your medications into the Medicare Plan Finder to see which plan minimizes annual out-of-pocket spending across your full regimen [7].